Bioventus Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-156.23	-158.7	19.38	16.41	6.85	-17.99
Depreciation & Amortization	57.37	55.4	34.88	28.64	30.32	29.24
Share-Based Compensation	2.72	17.59	-7.29	10.1	11.41	15.33
Other Operating Activities	111.49	72.18	-23.97	16.64	-7.86	12.82
Operating Cash Flow	15.34	-13.54	22.99	71.8	40.71	45.19
Operating Cash Flow Growth	-	-	-67.98%	76.35%	-9.90%	-
Capital Expenditures	-7.36	-10.04	-13.52	-16.58	-2.34	-2.56
Acquisitions	34.68	-1.48	-270.24	-4.09	-5.57	-3.5
Other Investing Activities	-11.51	-104.92	-	0.17	-	-0.04
Investing Cash Flow	15.81	-116.44	-283.76	-20.5	-7.91	-6.1
Dividends Paid	0	0	0	-19.89	-9.14	-7.85
Share Issuance / Repurchase	0.78	5.82	109.41	0	0	0
Debt Issued / Paid	-23.26	59.62	166.2	-10	-1.37	-5.25
Other Financing Activities	-4.17	-3.37	-2.24	0.32	-0.45	-0.16
Financing Cash Flow	-26.65	62.08	273.37	-29.57	-10.95	-13.26
Exchange Rate Effect	0.63	0.52	-0.23	0.59	-0.1	-0.16
Net Cash Flow	5.13	-67.38	12.37	22.32	21.75	25.67
Free Cash Flow	7.98	-23.58	9.47	55.22	38.37	42.63
Free Cash Flow Growth	-	-	-82.85%	43.91%	-9.98%	-
Free Cash Flow Margin	1.56%	-4.60%	2.20%	17.19%	11.28%	13.35%
Free Cash Flow Per Share	0.13	-0.38	0.21	11.27	7.83	8.70

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).